Management of recurrent hepatitis C after liver transplantation: a concise review
Department of Medicine, Division of Gastroenterology
Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Prognosis; RNA, Viral; Recurrence; Ribavirin
Gastroenterology | Hepatology
Recurrent hepatitis C infection and subsequent graft failure are increasingly recognized problems after orthotopic liver transplantation. Although many prospective therapeutic, controlled trials in primary hepatitis C disease have been reported, large-scale studies are yet to be performed in patients with posttransplant recurrent hepatitis C after liver transplantation. In this review, we summarize the current literature on the therapeutic approaches for recurrent hepatitis C and discuss the results of published studies on therapy with ribavirin or interferon (IFN) alone and on combination therapy with IFN plus ribavirin. Further, we discuss results of prophylactic approaches to the problem of recurrent hepatitis C after transplant. Finally, we discuss additional aspects of anti-hepatitis C virus therapy after liver transplantation.
Rights and Permissions
Citation: Am J Gastroenterol. 2000 Sep;95(9):2164-70. Link to article on publisher's site
The American journal of gastroenterology
Szabo, Gyongyi; Katz, Eliezer; and Bonkovsky, Herbert L., "Management of recurrent hepatitis C after liver transplantation: a concise review" (2000). Gastroenterology Publications and Presentations. 29.